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Abstract For the epigenetic characterization of neuromyelitis
optica (NMO), we determined whether messenger RNAs
(mRNAs) and long noncoding RNAs (lncRNAs) are
expressed differentially in subjects with and without NMO.
lncRNA and mRNA expression profiles of NMO patients and
healthy controls were generated by using microarray analysis.
For comparison, the differentially expressed mRNA functions
were annotated by using gene ontology (GO) and pathway
analyses. The microarray revealed that 1310 lncRNAs and
743 mRNAs differed in NMO patients from those in healthy
controls. Pathway analysis then demonstrated that IL23-
mediated signaling events, interferon gamma signaling, natu-
ral killer (NK)-κB signaling pathway, chemokine receptors
that bind chemokines, GPCR ligand binding, and metabolic
disorders of biological oxidation enzyme pathways play im-
portant roles in NMO. Several GO terms including cytokine
stimulus, response to cytokine, immune response, cytokine-
mediated signaling pathway, and response to chemical cyto-
kine activity were enriched in gene lists, suggesting a potential
correlation with NMO. Co-expression network analysis indi-
cated that 183 lncRNAs and 458 mRNAswere included in the
co-expression network. Our present study showed that these
differentially expressed mRNAs and lncRNAs may play im-
portant roles in NMO and could provide basic information for
new biomarkers or treatment targets to alleviate NMO.
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Introduction
Neuromyelitis optica (NMO) is characterized by severe attacks
of optic neuritis and/or longitudinally extensive transverse mye-
litis [1]. A significant proportion of NMO patients are seroposi-
tive for antibodies that target aquaporin-4 [2], the main water
channel in the central nervous system (CNS), and specifically
localize to astrocyte processes [3]. However, the epigenetic char-
acteristics of this disease are not completely understood.
Long noncoding RNAs (lncRNAs) are typified by a length of
transcription longer than 200 nucleotides that is not translated
into proteins [4]. Increasing scientific interest in these factors
stems from previous investigations showing that lncRNAs exert
their regulatory effects on gene expression levels, involving epi-
genetic regulation, transcriptional regulation, and post-
transcriptional regulation in the form of RNA [5]. IncRNAs also
play important roles in modulating innate and adaptive immune
responses and immune cell development [6]. Moreover, emerg-
ing evidence suggests the decisive participation of lncRNAs in
such autoimmune diseases as systemic lupus erythematosus
(SLE), rheumatoid arthritis (RA), type 1 diabetes mellitus
(T1DM), and multiple sclerosis (MS) [7].
A comprehensive understanding of the epigenetic and mo-
lecular disorders of the disease is the key to early diagnosis,
appropriate treatment, and better prognosis for patients with
NMO. Therefore, the present study was initiated to use
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lncRNA microarray for the characterization of genome-wide
lncRNA and messenger RNA (mRNA) expression profiles of
NMO patients compared with healthy controls. Our goal was
to establish the potential utility of lncRNAs as biomarkers of
or treatment targets for NMO.
Materials and Methods
Patients and Sample Collection
For this study, we enrolled 16 patients who had been diag-
nosed with NMO according to the revised diagnostic criteria
as proposed by Wingerchuk [8] in 2015 in Tianjin Medical
University General Hospital between 2014 and 2015. These
patients were within the peak timing of manifesting NMO and
before treatment with glucocorticoid or intravenous immune
globulin. We also recruited 16 age- and gender-matched
healthy controls for the comparative study. The demographic
and clinical features of all the patients and healthy controls are
summarized in Table 1. Sera antiaquaporin 4 (AQP4) anti-
body was detected by the cell-based assay (CBA) as described
in a previous study [9]. Informed consent was obtained at
enrollment from all patients or legally acceptable surrogates.
Peripheral blood anticoagulated with ethylene diamine
tetraacetic acid (EDTA) was obtained from all NMO patients
and healthy controls. Human peripheral blood mononuclear
cells (PBMCs) were isolated with Ficoll-Hypaque gradients.
The present study was approved by the ethics committee of
Tianjin Medical University General Hospital.
RNA Extraction
For RNA purification, we used TRIzol reagent (Invitrogen,
Grand Island, NY,USA) according to themanufacturer’s instruc-
tions followed by application of PBMCs to RNeasy spin col-
umns (Qiagen, Venlo, Limburg, Netherlands). Quantification
and quality evaluation were performed by using a Nanodrop
and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA), respectively.
lncRNA Microarray
The Human IncRNA Microarray V3.0 (Arraystar, Rockville,
MD, USA) was used to design the global profiling of human
lncRNAs and protein-coding transcripts. The third-generation
lncRNA microarray detects approximately 30,586 lncRNAs
and 26,109 coding transcripts. The lncRNAs were carefully
constructed using the most highly respected public tran-
scriptome databases (RefSeq, UCSC Known Genes, and
Genecode, etc.), as well as landmark publications. A specific
exon or splice junction probe was used to represent each tran-
script that could accurately identify individual transcripts. In
addition, positive probes for housekeeping genes and negative
probes were printed onto the array to hybridize quality control.
GeneSpring GX v11.5.1 software (Agilent Technologies) was
used to extract and normalize the data. Volcano Plot filtering
and hierarchical clustering were used to identify the differen-
tially expressed lncRNAs and mRNAs that reached the level
of statistical significance. Differentially expressed
lncRNAs and mRNAs were identified through the ran-
dom variance model with P values calculated by the
paired t test. The significance cutoff for the upregulated
and downregulated lncRNAs and mRNAs was a fold
change ≥2.0 with P ≤ 0.05.
qRT-PCR Validation
To validate the microarray data, we randomly selected three up-
r e g u l a t e d l n c RNA s ( EN SG 0 0 0 0 0 2 2 4 2 9 8 . 2 ,
TCONS_00026848, XR_110877.1) from aberrantly expressed
lncRNAs. Moreover, we also randomly selected three downreg-
ulated lncRNAs (ENST00000563502.1, ENST00000436293.2,
and TCONS_00017068).
Table 1 Baseline characteristics
Control (n= 16) NMO (n= 16) P value
Gender, F/M 14/2 14/2 1.00
Age at onset, median (range) (years)
Disease duration, median (range) (years)










EDSS score, median (range) – 4 (2–8) –
OCBs positive/tested (%)
VEP (%)
Brain MRI abnormalities (%)













LESCL (%) – 16/16 (100) –
NMO neuromyelitis optica, EDSS Kurtzke Expanded Disability Status Scale, OCBs oligoclonal bands, VEP
visual evoked potential, MRI magnetic resonance imaging, LESCL longitudinally extensive spinal cord lesions
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Quantitative real-time reverse transcription PCR (qRT-
PCR) is the gold standard for data verification in this context.
For the reverse transcriptase (RT) reaction, SYBR Green RT
reagents (Bio-Rad, USA) were used. In brief, the RT reaction
was performed for 60 min at 37 °C, followed by 60 min at
42 °C, using oligo (dT) and random hexamers. PCR amplifi-
cations were performed by using SYBR Green Universal
MasterMix. These reactions were performed in duplicate con-
taining 2× concentrated Universal Master Mix, 1 μL of tem-
plate cDNA, and 100 nM of primers in a final volume of
12.5 μL, followed by analysis in a 96-well optical reaction
plate (Bio-Rad). The lncRNA PCR results were quantified by
using the 2ΔΔct method against β-actin for normalization.
These data represent the means of three experiments.







GO and Pathway Analysis
Gene ontology (GO) analysis was performed to characterize
genes and gene products in terms of cellular components, mo-
lecular functions, and biological processes. Pathway analysis is
an effectivemethod for predicting the underlying biological func-
tions of the differentially expressed genes [10]. This analysis was
used to determine the main pathways in which differentially
expressed mRNAs underwent significant enrichment. The P
values and false discovery rate denoted the significance of GO
term enrichment and the biological pathways in the differentially
expressed mRNA list (recommended P value <0.05).
IncRNA-mRNA Co-Expression Network
The IncRNA-mRNA co-expression network identifies inter-
actions between differentially expressed mRNAs and differ-
entially expressed lncRNAs. The basis of this construct is the
normalized signal intensities of specific expression levels of
mRNAs and lncRNAs. To formulate the lncRNA-mRNA co-
expression network used here, we applied Pearson’s correla-
tions, to calculate statistically significant associations.
Statistical Analysis
All statistical data were analyzed by using SPSS 17.0 software
(SPSS Inc., Chicago, IL, USA). lncRNAs and mRNAs
expressed differentially in NMO patients compared to healthy
controls were analyzed by using Student’s t tests. Statistical
significance was considered as P<0.05.
Results
lncRNA and mRNA Profiles Differ in Patients with NMO
and in Healthy Controls
Human LncRNA Array v3.0 was used to detect lncRNAs in
PBMC from five NMO patients and five healthy controls.
Volcano plot analysis was then applied for the direct identifi-
cation of differences in lncRNAs and mRNAs from these two
populations (Fig. 1a, b). Next, a hierarchical clustering tech-
nique enabled us to separate the NMO patients from controls
in terms of gene expression data (Fig. 2a, b). With a 2/
0.5-fold change as the cutoff, a total of 1310 lncRNAs
were specifically dysregulated, including 862 upregulat-
ed lncRNAs and 448 downregulated lncRNAs, respec-
tively, in NMO patients compared with controls. In ad-
dition, 743 differentially expressed mRNAs reached the level
of statistical significance in NMO patients compared to
healthy controls. Of those, 441 were upregulated and 302
were downregulated.
qRT-PCR Validation
To validate our results independently and determine the role of
lncRNAs inNMO,we randomly selected six lncRNAs from 862
upregulated lncRNAs and 448 downregulated lncRNAs in
NMO patients for comparison to healthy controls. As shown in
Fig. 3, of these six lncRNAs that that differed in NMO patients
versus healthy controls, IncRNA ENSG00000224298.2 was the
most elevated (10.05-fold higher expression), followed by
lncRNA TCONS_00026848 (5.68-fold higher expression) and
lncRNA XR_110877.1 (5.53-fold higher expression).
IncRNAENST00000563502.1, lncRNAENST00000436293.2,
and lncRNATCONS_00017068 exhibited 8.3-, 6.13-,
and 2.96-fold lower expression, respectively. These re-
sults were consistent with those obtained from the mi-
croarray chip analyses.
GO and Pathway Analysis
To evaluate the enrichment of mRNAs in biological processes,
cellular components, and molecular functions, GO analysis
was performed on 743 significantly dysregulatedmRNAs not-
ed from the microarray outcomes (Supplementary data 1). GO
analysis of relevant factors from the upregulated mRNAs in-
cluded cellular response to cytokine stimulus, response to cy-
tokine, immune response, cytokine-mediated signaling path-
way, and response to chemical cytokine activity (Fig. 4a).
However, GO analysis of the downregulated mRNAs in-
volved factors of learning or memory, cognition, single-
organism behavior, and regulation of synaptic plasticity
(Fig. 4b). Subsequent pathway analysis showed that aberrant-
ly upregulated mRNAs were involved in IL23-mediated
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signaling events, interferon gamma signaling, the natural kill-
er (NK)-κB signaling pathway, chemokine receptors bind
chemokines, guanosine-binding protein-coupled receptor
(GPCR) ligand binding, and metabolic disorders of biological
oxidation enzymes (Fig. 5a). Dissimilarly, results from path-
way analysis of the downregulated mRNAs selected long-
term potentiation, taste transduction, Ca2+ pathway, and the
ras-independent pathway in NK cell-mediated cytotoxicity
(Fig. 5b) as distinctive features.
IncRNA-mRNA Co-Expression Network
Co-expression network analysis was then performed to char-
acterize the 1310 differentially expressed lncRNAs and the
743 differentially expressed mRNAs. In total, 183 lncRNAs
and 458 mRNAs were included in the co-expression network
(Supplementary data 2). Our data showed that the co-
expression network was composed of 641 network nodes and
6879 connections. Review of the co-expression network indi-
cated that one mRNAmay correlate with 1 to 96 lncRNAs, and
one lncRNAmay correlate with 1 to 96 mRNAs. Moreover, as
Fig. 4 reveals, the lncRNA-mRNA co-expression network was
operative in some meaningful GO and pathway analyses. That
is, 43 lncRNAs interacted with 5 mRNAs in the BNK-κB sig-
naling pathway^ (Fig. 6a), 59 lncRNAs interacted with 10
mRNAs in the GO of Bcytokine-mediated signaling pathway^
(Fig. 6b), 58 lncRNAs interacted with 9 mRNAs in the
GO of Bcytokine activity^ (Fig. 6c), and 69 lncRNAs
interacted with 14 mRNAs in the GO of Bcellular response
to cytokine stimulus^ (Fig. 6d).
Fig. 1 IncRNAs and mRNA profile comparisons between NMOpatients
and healthy controls. Volcano plots were used to distinguish the
differentially expressed lncRNAs (a) and mRNAs (b). The vertical
lines correspond to 2-fold upregulation or downregulation, and the hori-
zontal lines represent P= 0.05. The red points highlight the upregulated
genes, and the green points reflect the downregulated genes
Fig. 2 Cluster analysis of
differentially expressed lncRNAs
andmRNAs ofNMO patients and
healthy controls. Hierarchical
clustering analysis indicated 1310
lncRNAs (a) and 743 mRNAs (b)
that were differentially expressed
between NMO patients (N1–N5)
and healthy controls (C1–C5).
Respectively, the red and the
green shades represent the
expression levels above and
below the relative expression
among all samples
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Discussion
With the forefront technology ofmicroarray analysis, we dem-
onstrated here for the first time the expression profiles of hu-
man lncRNAs and mRNAs in patients with NMO. Compared
to healthy, matched controls, these NMO patients expressed
1310 lncRNAs and 743 mRNAs that were not present in the
controls. Moreover, we identified potential functions of these
differentially expressed mRNAs with GO and pathway
analyses.
IncRNAs are a new class of noncoding RNAs larger than
200 nucleotides. Previously, the involvement of lncRNAs in
immune cell development has been reported, including den-
dritic cell differentiation, T cell activation, granulocytic differ-
entiation, inhibition of T cell proliferation, Th1 cell differen-
tiation, regulation interferon gamma (IFN-γ) expression, reg-
ulation of CD4+ Th2 lymphocyte migration, and CD4+ helper
T lymphocyte differentiation [7, 11–14]. Moreover, lncRNAs
have been recognized as powerful regulators of numerous
genes and pathways in the pathogenesis of inflammatory
and autoimmune diseases, including SLE, RA, T1DM, MS,
autoimmune thyroid disease, psoriasis, and Crohn’s disease
[7, 15–17].
NMO is an inflammatory autoimmune disease of the CNS
that affects both the spinal cord and optic nerves.
Approximately 75 % of NMO patients are seropositive for
autoantibodies against the astrocyte water channel aquapo-
rin-4, resulting in astrocyte injury and inflammation [18].
However, because we sought to characterize the epigenetic
nature of this disease, the present study was undertaken to
investigate the differentially expressed lncRNAs and
mRNAs in NMO patients compared to healthy controls.
Designed for the global profiling of human lncRNAs and
protein-coding transcripts, the lncRNA microarray V3.0 sys-
tem was used here to screen the aberrant lncRNAs in five
NMO patients to distinguish them from those in five healthy
Fig. 3 Validation of lncRNA microarray data by qRT-PCR. Three
upregulated and three downregulated lncRNAs were validated by qRT-
PCR of RNA extracted from PBMCs of 16 NMO patients and 16 healthy
controls. The relative expression level of each lncRNA (a upregulated
lncRNAs, b downregulated lncRNAs) was normalized, and data
displayed in histograms are expressed as means ± SD, **P< 0.01 com-
paring NMO patients with healthy controls
Fig. 4 Gene ontology. A total of
743 differentially expressed
mRNAs were chosen in GO
analysis. The column graphs
represent the enrichment of these
mRNAs, and the (−lgP) value has
a positive correlation with GO. a
The top 10 GOs that were
upregulated in the NMO patients
compared to the healthy controls.
b The top 10 GOs that were
downregulated in the NMO
patients compared to the healthy
controls
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controls. Upon comparing lncRNA and mRNA expression
profiles of NMO patients and controls, we found that 1310
lncRNAs (862 upregulated and 448 downregulated
lncRNAs) and 743 mRNAs (441 upregulated and 302
downregulated mRNAs) were differentially expressed
between NMO patients and healthy controls. In the ear-
ly stage of NMO, the spinal cord lesion and optic nerve
lesion may be not typical, which make it difficult to
diagnosis. Therefore, more and more researches focused
on finding new technique in early diagnosis of NMO.
Our present study may provide basic information of
using these differentially expressed lncRNAs and
mRNAs in early diagnosis of NMO.
GO and pathway analyses were performed to obtain de-
tailed information on the biological functions and potential
mechanisms of these differentially expressed lncRNAs and
mRNAs. A total of 743 filtered mRNAs (2-fold change) were
included in GO and pathway analyses. GO analysis re-
vealed that 441 upregulated mRNAs were involved in
cellular responses to cytokine stimulus, responses to cy-
tokines, immune responses, the cytokine-mediated signaling
pathway, responses to chemicals, and cytokine activity
(Fig. 4a). However, 302 downregulated mRNAs were partic-
ipants in learning or memory, cognition, memory, single-
organism behavior, and regulation of synaptic plasticity
(Fig. 4b). Pathway analysis of the 441 upregulated mRNAs
denoted their involvement in IL23-mediated signaling events,
IFN-γ signaling, the NF-κB signaling pathway, chemokine
receptor binding of chemokines, GPCR ligand binding, and
metabolic disorders of biological oxidation enzymes (Fig. 5a).
However, 302 downregulated mRNAs were functional in
long-term potentiation, taste transduction, the Ca2+ pathway,
and ras-independent pathway in NK cell-mediated cytotoxic-
ity (Fig. 5b).
Astrocytes, the most abundant cell type in the CNS, are
highly sensitive to environmental cues and are implicated in
both detrimental and protective outcomes during autoimmune
demyelination. As the hallmark cytokine of Th1 cells, IFN-γ
plays an important role in the activity of astrocytes in autoim-
mune inflammation of the CNS. IFN-γ also functioned as a
proinflammatory cytokine in the early stage of experimental
allergic encephalomyelitis (EAE) [19–21]. Elsewhere, si-
lencing IFN-γ signaling in astrocytes attenuated chemo-
kine expression and inflammatory cell infiltration into
the CNS in EAE [22]. In the present study, pathway
analysis showed that IFN-γ signaling was upregulated
in NMO patients compared with that in healthy con-
trols, which may also indicate an important role of
IFN-γ in astrocytes’ functionality of those with NMO.
Also, GPCRs have been implicated in elevated astrocyte
molecular networks and astrocyte calcium signaling after
inflammatory stimuli [23]. In accord, we also found an
abundant upregulation of mRNA involvement in GPCR
ligand binding. Others have indicated that inhibiting the
NF-κB signal transducer pathway can reduce neuroin-
flammation in astrocytes [24, 25]. In the present study,
since the NF-κB signaling pathway was notably upreg-
ulated in NMO patients compared with their healthy
counterparts, conceivably, the NF-κB signaling pathway
could provide a treatment strategy for NMO.
Fig. 5 Pathway analyses. A total
of 743 differentially expressed
mRNAs were chosen in pathway
analyses. Column graphs
represent the enrichment of these
mRNAs, and the (−lgP) value has
a positive correlation with
pathway analyses. a The top 10
pathways that were upregulated in
the NMO patients compared to
healthy controls. b The top 10
pathways that were
downregulated in the NMO
patients compared to healthy
controls
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The co-expression network analysis cited here was con-
structed based on the 1310 differentially expressed lncRNAs
and the 743 differentially expressed mRNAs that distin-
guished NMO patients from control subjects. Our results
showed that a total of 183 lncRNAs and 458 mRNAs were
included in the co-expression network. Analysis of this co-
expression network, which was composed of 641 network
nodes and 6879 connections, indicated that one lncRNA could
target at most 96 mRNAs, and one mRNA could correlate
with at most 96 lncRNAs. We also found that 43 lncRNAs
interacted with 5 mRNAs involved in the meaningful NK-κB
signaling pathway (Fig. 6a), 59 lncRNAs interacted with 10
mRNAs involved in the GO of cytokine-mediated signaling
pathway (Fig. 6b), 58 lncRNAs interacted with 9 mRNAs
involved in the GO of cytokine activity (Fig. 6c), and 69
lncRNAs interacted with 14 mRNAs involved in the GO of
cellular response to cytokine stimulus (Fig. 6d).
In conclusion, the foregoing outcome, demonstrated here
for the first time, suggests that the inter-regulation of lncRNAs
and mRNAs may either perpetuate the development of NMO
or, alternatively, provide basic information much needed for
recognizing and/or alleviating NMO.
Fig. 6 IncRNA-mRNA co-expression network. a Forty-three lncRNAs
interacted with five mRNAs in the meaningful BNK-κB signaling
pathway.^ b Fifty-nine lncRNAs interacted with ten mRNAs in the GO
of Bcytokine-mediated signaling pathway.^ c Fifty-eight lncRNAs
interacted with nine mRNAs in the GO of Bcytokine activity.^ d Sixty-
nine lncRNAs interacted with 14 mRNAs in the GO of Bcellular response
to cytokine stimulus^
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